cAMP during HIV infection: Friend or foe?

AIDS Research and Human Retroviruses

Volumn 28, Issue 1, 2012, Pages 49-53

  Moreno Fernandez, Maria E ^a   Rueda, Cesar Mauricio ^b   Velilla, Paula A ^b   Rugeles, Maria Teresa ^b   Chougnet, Claire A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CD39 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHOLERA TOXIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; G PROTEIN COUPLED RECEPTOR; GAP JUNCTION PROTEIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; ISOPROTEIN; PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR ALPHA;

ADENOSINE DIPHOSPHATE RIBOSYLATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVATION; EXTRACELLULAR SPACE; GAP JUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOREGULATION; INTRACELLULAR MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL; VIRAL CLEARANCE; VIRUS REPLICATION;

CYCLIC AMP; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; VIRUS REPLICATION;

EID: 84855593887     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0265     Document Type: Review

References (63)

1. Watts VJ and Neve KA: Sensitization of adenylate cyclase by Galpha i/o-coupled receptors. Pharmacol Ther 2005;106(3): 405-421. (Pubitemid 40726295)
2. Sunahara RK and Taussig R: Isoforms of mammalian adenylyl cyclase: Multiplicities of signaling. Mol Interv 2002; 2(3):168-184.
3. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995;75(4): 725-748.
4. 4+ T cells. Mol Immunol 2010;47(4):678-684.
5. Marson A, Kretschmer K, Frampton GM, et al.: Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007;445(7130):931-935.
6. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, and Rudensky AY: Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445(7130):936-940.
7. Omori K and Kotera J: Overview of PDEs and their regulation. Circ Res 2007;100(3):309-327.
8. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, and Ohta A: Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 2008;153(Suppl 1):S457-464. (Pubitemid 351341019)
9. Fonseca PC, Nihei OK, Savino W, Spray DC, and Alves LA: Flow cytometry analysis of gap junction-mediated cell-cell communication: advantages and pitfalls. Cytometry A 2006; 69(6):487-493. (Pubitemid 44651335)
10. Bopp T, Becker C, Klein M, et al.: Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007;204(6):1303-1310. (Pubitemid 46919868)
11. Ring S, Karakhanova S, Johnson T, Enk AH, and Mahnke K: Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8( + ) T cells. J Allergy Clin Immunol 2010;125(1):237-246.
12. Gray PC, Scott JD, and Catterall WA: Regulation of ion channels by cAMP-dependent protein kinase and A-kinase anchoring proteins. Curr Opin Neurobiol 1998;8(3):330-334. (Pubitemid 28288567)
13. Kwok RP, Lundblad JR, Chrivia JC, et al.: Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994;370(6486):223-226. (Pubitemid 24236779)
14. Gupta A and Terhorst C: CD3 delta enhancer. CREB interferes with the function of a murine CD3-delta A binding factor (M delta AF). J Immunol 1994;152(8):3895-3903. (Pubitemid 24111061)
15. Borger P, Postma DS, Vellenga E, and Kauffman HF: Regulation of asthma-related T-cell cytokines by the cyclic AMPdependent signalling pathway. Clin Exp Allergy 2000; 30(7):920-926. (Pubitemid 30427032)
16. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, and Tasken K: Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 2002;14(1):1-9. (Pubitemid 34020823)
17. Bryce PJ, Dascombe MJ, and Hutchinson IV: Immunomodulatory effects of pharmacological elevation of cyclic AMP in T lymphocytes proceed via a protein kinase A independent mechanism. Immunopharmacology 1999;41(2): 139-146. (Pubitemid 29099826)
18. Staples KJ, Bergmann M, Tomita K, et al.: Adenosine 3′,5′- cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMPdependent protein kinase A. J Immunol 2001;167(4):2074-2080. (Pubitemid 32747515)
19. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, and Nadler LM: Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science 1997; 278(5335):124-128. (Pubitemid 27446291)
20. Garay J, D'Angelo JA, Park Y, et al.: Crosstalk between PKA and Epac regulates the phenotypic maturation and function of human dendritic cells. J Immunol 2010;185(6):3227-3238.
21. Johansson CC, Bryn T, Yndestad A, et al.: Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP. AIDS 2004; 18(2):171-179. (Pubitemid 38253438)
22. Gerlo S, Verdood P, and Kooijman R: Modulation of cytokine production by cyclic adenosine monophosphate analogs in human leukocytes. J Interferon Cytokine Res 2010; 30(12):883-891.
23. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, and Ernst PB: Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol 2006;177(5):2765-2769. (Pubitemid 44277790)
24. 4+ T cells. Eur J Immunol 2009;39(5):1301- 1312.
25. Sakata D, Yao C, and Narumiya S: Prostaglandin E2, an immunoactivator. J Pharmacol Sci 2010;112(1):1-5.
26. Vendetti S, Patrizio M, Riccomi A, and De Magistris MT: Human CD4 + T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP. J Leukoc Biol 2006;80(4):880-888. (Pubitemid 44835906)
27. Vendetti S, Riccomi A, Sacchi A, Gatta L, Pioli C, and De Magistris MT: Cyclic adenosine 5′-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4 + T lymphocytes. J Immunol 2002;169(11):6231-6235. (Pubitemid 36903469)
28. Zhou W, Hashimoto K, Goleniewska K, et al.: Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007;178(2):702-710. (Pubitemid 46095142)
29. Ben Addi A, Lefort A, Hua X, et al.: Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol 2008;38(6):1610-1620.
30. Nemeth ZH, Lutz CS, Csoka B, et al.: Adenosine augments IL-10 production by macrophages through an A2B receptormediated posttranscriptional mechanism. J Immunol 15 2005;175(12):8260-8270. (Pubitemid 41798391)
31. Hasko G, Kuhel DG, Chen JF, et al.: Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptordependent and independent mechanisms. FASEB J 2000; 14(13):2065-2074.
32. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, and Vizi ES: Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157(10):4634-4640. (Pubitemid 126449386)
33. Wilson JM, Ross WG, Agbai ON, et al.: The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol 2009;182(8):4616-4623.
34. Son Y, Ito T, Ozaki Y, et al.: Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. Immunology 2006;119(1):36-42. (Pubitemid 44201154)
35. Borsellino G, Kleinewietfeld M, Di Mitri D, et al.: Expression of ectonucleotidase CD39 by Foxp3 + Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110(4):1225-1232. (Pubitemid 47281420)
36. Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al.: Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008;112(5):1822-1831.
37. Yaqub S and Tasken K: Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog 2008;14(1):57-77.
38. Bopp T, Dehzad N, Reuter S, et al.: Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol 2009;182(7):4017- 4024.
39. Nokta M and Pollard R: Human immunodeficiency virus infection: Association with altered intracellular levels of cAMP and cGMP in MT-4 cells. Virology 1991;181(1):211-217.
40. Hofmann B, Nishanian P, Nguyen T, Insixiengmay P, and Fahey JL: Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes. Proc Natl Acad Sci USA 1993;90(14):6676-6680. (Pubitemid 23207276)
41. Aandahl EM, Aukrust P, Skalhegg BS, et al.: Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J 1998;12(10):855-862. (Pubitemid 28294675)
42. Hofmann B, Nishanian P, Nguyen T, Liu M, and Fahey JL: Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues. AIDS 1993;7(5):659-664. (Pubitemid 23204958)
43. Andersson J, Boasso A, Nilsson J, et al.: The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005;174(6):3143-3147. (Pubitemid 40354012)
44. Nilsson J, Boasso A, Velilla PA, et al.: HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006;108(12): 3808-3817. (Pubitemid 44864563)
45. Estes JD, Li Q, Reynolds MR, et al.: Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis 2006;193(5):703-712. (Pubitemid 43271504)
46. Epple HJ, Loddenkemper C, Kunkel D, et al.: Mucosal but not peripheral FOXP3 + regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 2006;108(9):3072-3078.
47. Masci AM, Galgani M, Cassano S, et al.: HIV-1 gp120 induces anergy in naive T lymphocytes through CD4- independent protein kinase-A-mediated signaling. J Leukoc Biol 2003;74(6):1117-1124. (Pubitemid 38040334)
48. Becker C, Taube C, Bopp T, et al.: Protection from graftversus- host disease by HIV-1 envelope protein gp120-mediated activation of human CD4 + CD25 + regulatory T cells. Blood 2009;114(6):1263-1269.
49. Leal DB, Streher CA, Bertoncheli Cde M, et al.: HIV infection is associated with increased NTPDase activity that correlates with CD39-positive lymphocytes. Biochim Biophys Acta 2005;1746(2):129-134. (Pubitemid 41774287)
50. Schulze Zur Wiesch J, Thomssen A, Hartjen P, et al.: Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3 + T regulatory cells correlates with progressive disease. J Virol 2011;85(3):1287-1297.
51. Nikolova M, Carriere M, Jenabian MA, et al.: CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011;7(7):e1002110.
52. Nigam P, Velu V, Kannanganat S, et al.: Expansion of FOXP3 + CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control. J Immunol 2010;184(4):1690-1701.
53. Séror C, Melki M-T, Subra F, et al.: Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med 2011;208(9):1823-1834.
54. Navarro J, Punzon C, Jimenez JL, et al.: Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol 1998; 72(6):4712-4720. (Pubitemid 28215646)
55. Sun Y, Li L, Lau F, Beavo JA, and Clark EA: Infection of CD4 + memory T cells by HIV-1 requires expression of phosphodiesterase 4. J Immunol 2000;165(4):1755-1761. (Pubitemid 30643124)
56. 4+ T lymphocytes. Retrovirology 2008;5:30.
57. Banas B, Eberle J, Schlondorff D, and Luckow B: Modulation of HIV-1 enhancer activity and virus production by cAMP. FEBS Lett 2001;509(2):207-212. (Pubitemid 34015944)
58. Rincon M, Tugores A, Lopez-Rivas A, et al.: Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol 1988;18(11):1791-1796. (Pubitemid 19011589)
59. Hayes MM, Lane BR, King SR, Markovitz DM, and Coffey MJ: Prostaglandin E(2) inhibits replication of HIV-1 in macrophages through activation of protein kinase A. Cell Immunol 2002;215(1):61-71.
60. Thivierge M, Le Gouill C, Tremblay MJ, Stankova J, and Rola-Pleszczynski M: Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocytederived macrophages: Downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood 1998;92(1):40-45. (Pubitemid 28303173)
61. 4+ T-cells. Hum Immunol 2010;71(11):1073-1076.
62. Moreno-Fernandez ME, Rueda CM, Rusie LK, and Chougnet CA: Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 2011;117(20):5372-5380.
63. Fuld S, Borland G, and Yarwood SJ: Elevation of cyclic AMP in Jurkat T-cells provokes distinct transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC) pathways. Exp Cell Res 2005;309(1):161-173. (Pubitemid 41191232)